NasdaqGS:DYNBiotechs
How Investors Are Reacting To Dyne Therapeutics (DYN) Launching Phase 3 FORZETTO Trial For DYNE-251
Dyne Therapeutics recently initiated the global, randomized, placebo-controlled Phase 3 FORZETTO trial of zeleciment rostudirsen (DYNE-251) in ambulatory males aged 4 to 18 with Duchenne muscular dystrophy amenable to exon 51 skipping, following alignment on the design with the U.S. FDA.
A key feature for investors is that FORZETTO is intended as the confirmatory study to support converting a potential U.S. Accelerated Approval to traditional approval and to underpin ex-U.S. marketing...